Stroma Genomic Signature Predicts Resistance To Anthracyclin-based Chemotherapy In Breast Cancer, Swiss Institute of Bioinformatics - SWISS-PROT Study

ScienceDaily (Feb. 11, 2009) — Researchers at the Swiss Institute of Bioinformatics and the Swiss National Center of Competence in Research in Molecular Oncology in Lausanne have developed a new test to predict how breast cancer patients respond to chemotherapy, which could help change how treatment is delivered in the future.